top


The Value "Upgrade": Pre-emptive Due Diligence (TM)

XOventure has a track record of increasing companies' value and attractiveness as investment and partnering target through our "pre-emptive due diligence" - a due diligence preparation and rehearsal by a multi-disciplinary team of top experts.

Fact Sheet


Unexpected questions and findings that surface during a due diligence occur far too often and may result in value adjustment or loss of the deal. Most of those can be avoided or mitigated easily by knowing upfront what a potential buyer or investor may look for and find in the company's records.

 

XOventure's Pre-emptive Due Diligence Process has the power to find and fix any issues relevant to potential collaborators, buyers or investors:
Dedicated senior experts with outstanding international experience
All disciplines within drug and device development in one cross-functional team, leading to a unique multidisciplinary process
Experience from Pharma and investor due diligence
Identification and prioritization of gaps and actions for value enhancement across the disciplines using due diligence methods
Coaching the management team to present and defend their case
A fast and cost-effective way to achieve due diligence excellence in Pharma/investor discussions
A proven value generating step for the individual programs
In sharp contrast to the buyer's due diligence, where identified flaws are mostly not pointed out to the seller, but nevertheless affect the outcome of the deal, we not only share all findings, but provide immediate remedy and/or action plans addressing the gaps.

XOventure's Pre-emptive Due Diligence Process has the power to find and fix any issues relevant to potential collaborators, buyers or investors:

  • Dedicated senior experts with outstanding international experience
  • All disciplines within drug and device development in one cross-functional team, leading to a unique multidisciplinary process
  • Experience from Pharma and investor due diligence
  • Identification and prioritization of gaps and actions for value enhancement across the disciplines using due diligence methods
  • Coaching the management team to present and defend their case
  • A fast and cost-effective way to achieve due diligence excellence in Pharma/investor discussions
  • A proven value generating step for the individual programs

In sharp contrast to the buyer's due diligence, where identified flaws are mostly not pointed out to the seller, but nevertheless affect the outcome of the deal, we not only share all findings, but provide immediate remedy and/or action plans addressing the gaps.

 

Last Updated on Thursday, 15 September 2011 13:13
 

News

COURSE
Drug Development:
Challenges & Solutions
May 23-25, 2011, Copenhagen
Pathology Experts
in collaboration with XOventure
More information
_____________
XOventure opens
new Copenhagen office:
Bagsværdvej 70A
DK-2800 Lyngby
Opening Reception
Feb 4, 2011
_____________
Managing Partner
Jørgen Thorball
receives Medicon Valley
Cross-Border Award
Oct 28, 2010
ReadXOventure GmbH established in Lucerne, central Switzerland!

 

Dec 2011:
2nd Drug Development Course

Registration open!
Pathology Experts & XOventure.
More Information 


Nov 2011: 
Entrepreneur of the Year

Immudex, a management buy-out from Dako led by XO win Ernst & Young's "Entrepreneur of the Year" 2011!


July 2011: XOventure GmbH 
XOventure GmbH established in Lucerne, central Switzerland!   


May 2011:
Success with course!
 
 
Drug Development: 
Challenges & Solutions 
Pathology Experts & XOventure.



bottom

Powered by Joomla!. Designed by: Joomla 1.5 Template, web space. Valid XHTML and CSS.